CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1159 (clinicaltrials.gov NCT No: NCT01711528)
Title:Phase 1 Clinical Trial of A Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Principal Investigator:Sheeba K. Thomas
Treatment Agent:Bortezomib; Dexamethasone; Dinaciclib
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of dinaciclib that can be given in combination with bortezomib and
dexamethasone.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Bortezomib
Dexamethasone
Dinaciclib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults